Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
September 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Cholangiocarcinoma
Cholangiocarcinoma
,
FDA Approvals
,
Conference Highlights ASCO
Truseltiq Second Targeted Therapy Approved for Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations
Read More
Cholangiocarcinoma
Emerging Molecular Targets in Cholangiocarcinoma: IDH1, HER2, BRAF, and Beyond
Read More
Cholangiocarcinoma
Targeted Therapies in Cholangiocarcinoma
Read More
Cholangiocarcinoma
Surgery for Cholangiocarcinoma
Read More
Cholangiocarcinoma
Expanding Treatment Options for Patients with Advanced Cholangiocarcinoma
Wayne Kuznar
Read More
Results 1 - 5 of 5
